Domov › Rak pljuč › Georgia › Atlanta
Klinične študije za Rak pljuč v Atlanta, GA
29 študij za Rak pljuč išče udeležence na lokacijah v Atlanta in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- Northside Hospital, Atlanta
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Vključevanje udeležencevFaza 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Atlanta VA Medical Center, Decatur · 6 mi stran
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- in še 1
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Vključevanje udeležencevFaza 3
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Vključevanje udeležencevFaza 3
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Vključevanje udeležencevFaza 3
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Vključevanje udeležencevFaza 2/3
- Piedmont Healthcare, Atlanta
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Vključevanje udeležencev
- Emory Clinic at Old Fourth Ward, Atlanta
- Emory Clinic at Midtown, Atlanta
- Emory at Peachtree Hills - Primary Care, Atlanta
- in še 19
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Vključevanje udeležencevFaza 1/2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Emory University, Atlanta
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, Atlanta
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Vključevanje udeležencevFaza 3
- Northside Hospital Atlanta, Atlanta
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Vključevanje udeležencevFaza 1
- Emory University - Winship Cancer Institute, Atlanta
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Grady Health System, Atlanta
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
- in še 3
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Vključevanje udeležencevFaza 1
- Xencor Investigative Site, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Vključevanje udeležencevFaza 1/2
- Winship Cancer Institute - Emory University, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Northside Hospital, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Vključevanje udeležencevFaza 1/2
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- in še 3
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Emory University Hospital/Winship Cancer Institute, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Vključevanje udeležencevZgodnja faza 1
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Vključevanje udeležencevFaza 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Vključevanje udeležencevOpazovalna študija
- Northside Hospital, Atlanta
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Emory University Hospital Midtown, Atlanta
- Emory University, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Atlanta
Študije za Rak pljuč v drugih mestih
- Houston, TX78 študij
- Boston, MA62 študij
- New York City, NY60 študij
- Los Angeles, CA45 študij
- Arlington, VA41 študij
- Washington, DC41 študij
- Chicago, IL41 študij
- Baltimore, MD40 študij
- Nashville, TN40 študij
- St. Louis, MO39 študij
- Columbus, OH37 študij
- Philadelphia, PA36 študij
Druge študije v Atlanta
- Rak (vse vrste)49 študij
- Nemalicelični pljučni rak47 študij
- Množni mielom42 študij
- Rak dojke41 študij
- Rak prostate33 študij
- Akutna mieločna levkemija31 študij
- Rak jajčnikov29 študij
- Kolorektalni rak29 študij
- Metastatski rak28 študij
- Velika depresivna motnja25 študij
- Srčno popuščanje25 študij
- Ploščatocelični karcinom glave in vratu24 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.